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ORIGINAL INVESTIGATION
Skin collagen fluorophore LW-1 
versus skin fluorescence as markers for  
the long-term progression of subclinical 
macrovascular disease in type 1 diabetes
David R. Sell1* , Wanjie Sun2, Xiaoyu Gao2, Christopher Strauch1, John M. Lachin2, Patricia A. Cleary2 
and Saul Genuth3, The DCCT/EDIC Research Group and Vincent M. Monnier1,4
Abstract 
Background: Skin collagen Long Wavelength Fluorescence (LWF) is widely used as a surrogate marker for accumula-
tion of advanced glycation end-products. Here we determined the relationship of LWF with glycemia, skin fluores-
cence, and the progression of complications during EDIC in 216 participants from the DCCT.
Methods: LW-1 and collagen-linked fluorescence (CLF) were measured by either High Performance Liquid Chroma-
tography (HPLC) with fluorescence detection (LW-1) or total fluorescence of collagenase digests (CLF) in insoluble 
skin collagen extracted from skin biopsies obtained at the end of the DCCT (1993). Skin intrinsic fluorescence (SIF) was 
noninvasively measured on volar forearm skin at EDIC year 16 by the SCOUT DS instrument.
Results: LW-1 levels significantly increased with age and diabetes duration (P < 0.0001) and significantly decreased 
by intensive vs. conventional glycemic therapy in both the primary (P < 0.0001) and secondary (P < 0.037) DCCT 
cohorts. Levels were associated with 13–16 year progression risk of retinopathy (>3 sustained microaneurysms, 
P = 0.0004) and albumin excretion rate (P = 0.0038), the latter despite adjustment for HbA1c. Comparative analysis 
for all three fluorescent measures for future risk of subclinical macrovascular disease revealed the following significant 
(P < 0.05) associations after adjusting for age, diabetes duration and HbA1c: coronary artery calcium with SIF and CLF; 
intima-media thickness with SIF and LW-1; and left ventricular mass with LW-1 and CLF.
Conclusions: LW-1 is a novel risk marker that is robustly and independently associated with the future progression of 
microvascular disease, intima-media thickness and left ventricular mass in type 1 diabetes.
Trial registration NCT00360815 and NCT00360893 at clinicaltrials.gov
Keywords: Glycation, Skin autofluorescence, HbA1c, Retinopathy, Nephropathy, Neuropathy
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zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Advanced glycation end-products (AGEs) are a highly 
diverse group of amino-carbonyl compounds whose 
formation is initiated by the reaction of reducing sugars 
and oxoaldehydes with proteins. Glucose nonenzymati-
cally reacts with free lysyl amino groups in proteins to 
form a Schiff base which rearranges to the more stable 
Amadori product [1]. The latter, in turn, undergoes a 
series of reactions to form insoluble, yellow, fluorescent 
and highly cross-linked products [2]. Protein-linked long 
wavelength fluorescence (LWF) ~ excitation (ex)/emission 
(em) 370/440 nm was introduced by us years ago as a sur-
rogate marker for AGE formation [3] and has since been 
widely used in both clinical and experimental studies of 
diabetes [4]. In skin essentially most of the LWF is linked 
to the insoluble collagen fraction as “collagen-linked 
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fluorescence” (CLF) which progressively increases with 
chronological age [2]. For CLF, insoluble collagen is 
prepared by extraction of skin and solubilized by enzy-
matic digestion to measure LWF [3]. Spectroscopically, 
diabetic samples show increased fluorescent intensity at 
370/440 nm compared with healthy control subjects [2]. 
However, CLF is unable to differentiate between fluo-
rophores with overlapping fluorescent spectra such as 
those derived from glycation vs. lipid peroxidation and 
other endogenous fluorophores [5–7].
In recent years, clinical interest in LWF as a marker 
of diabetic complications has rekindled with the devel-
opment of diagnostic devices capable of noninvasively 
measuring LWF in human forearm skin [8, 9]. Referred 
as skin autofluorescence (SAF) [9] or skin intrinsic fluo-
rescence (SIF) [8], these studies revealed strong correla-
tions between non-invasively measured LWF in skin 
from individuals with type 1 and type 2 diabetes and the 
presence of micro- and macrovascular complications 
[10, 11] which have been strongly associated with AGE 
formation. However, besides collagen, other interstitial, 
cellular and vascular components can exhibit autofluo-
rescence as well [12]. Additionally, the cause and effect 
relationship between the SAF/SIF readings and diabetic 
complications is not totally clear and there are numer-
ous confounding factors such as sex, ethnicity and race 
on the interpretation of the fluorescent measures made 
at broadband wavelengths, ex/em 375–456/435–655 nm. 
Thus, there is a pragmatic need to understand the chemi-
cal nature of skin autofluoresence as to specific AGE 
structures which presently is poorly understood [13].
In view of the fact that the biochemical nature of 
LWF and the role of glycation vs. oxidation in its for-
mation remains elusive [5, 14], we recently identified 
a major acid-labile fluorescent molecule with LWF 
in enzymatic digest of human insoluble skin collagen, 
named LW-1 [15]. In skin samples obtained at autopsy, 
levels were significantly elevated by age, diabetes, and 
end-stage renal disease. LW-1 has a molecular weight 
of 623 Da, a UV absorption maximum at ~348 nm and 
fluorescence maxima at ex/em 348/463  nm. Although 
its full chemical structure is still elusive, NMR analy-
sis showed that it has a lysine residue in an aromatic 
ring coupled to a sugar molecule that is reminiscent 
of AGEs [15]. Because of these findings, we wanted 
here to determine the relationship between LW-1 
vs. diabetes duration, glycemia and severity of com-
plications in patients with type 1 diabetes using skin 
biopsy samples from the Diabetes Control and Com-
plications Trial (DCCT) with long-term follow-up in 
the subsequent Epidemiology of Diabetes Interven-
tions and Complications (EDIC) study. Furthermore, 
because these patients have up to a tenfold higher risk 
for the development of cardiovascular disease (CVD) 
compared with the general population [16–18], we 
additionally wanted to investigate the comparative rela-
tionship of the aforementioned markers of LWF in skin; 
i.e. CLF, SIF and LW-1, to various indices of subclinical 
CVD previously assessed in the DCCT/EDIC cohort. 
These include coronary artery calcification (CAC), 
carotid artery intima-media thickness (IMT) and vari-
ous markers of myocardial dysfunction, particularly left 
ventricular hypertrophy/mass (LVM).
Methods
Study subjects
As previously described [19, 20], two 4  mm skin punch 
biopsies were obtained from the medial region of the 
right buttock from a total of 216 DCCT volunteers 
1–2  years prior to DCCT closeout in 1993. Informed 
consent for biopsies was collected from volunteers [19]. 
The biopsies were stored under argon at −80 °C and pro-
cessed as described in the recent publication [20]. Retin-
opathy, albumin excretion rate (AER), confirmed clinical 
neuropathy and HbA1c were assessed at DCCT closeout 
as described in detail elsewhere [21]. In addition, con-
senting subjects were followed in EDIC and retinopathy 
was assessed at least once during EDIC years 13–16 [22] 
in each subject ≈ one-fourth subjects per year. Biopsies 
were also obtained from 42 healthy individuals between 
ages 21 and 50 years as age-matched controls [19].
Biochemical standards
LW-1 was purified from an enzymatic digest of insoluble 
collagen extracted from a pool of human skin obtained 
by autopsy as previously described [15]. A standard 
was prepared based on published molecular data [15]. 
AGE standards including stable isotopes used as inter-
nal standards for fructosyl-lysine (i.e., Amadori prod-
uct), carboxymethyl-lysine (CML), carboxyethyl-lysine 
(CEL), glyoxal hydroimidazolone (G-H1), methylglyoxal 
hydroimidazolone (MG-H1) and glucosepane have been 
described elsewhere [23].
Processing of skin biopsies
The collagen digests used in this study were identical with 
those previously used for the determination of AGEs in 
the second skin punch biopsy [20]. Briefly, an insolu-
ble delipidated pellet (mean recovery per biopsy was 
7.2  mg; i.e., 92  %, range 72–100  %) was digested enzy-
matically and sequentially with collagenase, peptidase, 
pronase, and aminopeptidase as described [15] in order 
to release acid sensitive AGEs and LW-1 without destruc-
tion. Collagen content was determined in the digests by 
the hydroxyproline assay [24] assuming a content of 14 % 
hydroxyproline by weight [2].
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Measurement of LW‑1 by HPLC monitored by fluorescence
Each digest ~100 µl was filtered using a 3 kDa molecular 
weight cut-off (MWCO) 0.5 ml filtering device (Amicon 
Ultracel UFC5003, Millipore Corp., Billerica, MA) cen-
trifuged at 6000×g for ≈45–60 min (MRX-151 TOMY). 
An aliquot 14 µl of each digest (~66 ± 9 µg collagen) was 
injected onto a 15 cm × 2.1 mm, 3 µm Discovery HS C18 
column preceded by a 2  cm  ×  2.1  mm guard column 
same (Supelco-Sigma, St. Louis, MO). The HPLC, sol-
vents and gradient program were previously described 
by us [15]. Eluate from the column flowed onto a JASCO 
Model 821-FP fluorescence detector monitored at ex/
em 348/463  nm at gain 10×. Each chromatogram was 
integrated for the LW-1 peak area relative to that of the 
homemade LW-1 standard (Additional file  1) and the 
results were expressed as pmoles LW-1 per mg collagen 
measured by hydroxyproline assay in the acid hydrolysate 
of each digest.
Calculation of fluorescence recovery due to LW‑1
Fluorescence recovery attributable to LW-1 compared 
to CLF at ex/em 348/463 nm was determined by manu-
ally collecting the LW-1 peak eluting from the HPLC 
and comparing its fluorescence yield with that of the 
digest itself at wavelengths same. An enzyme blank was 
also injected into the HPLC and the eluate with the 
same retention time as LW-1 (i.e., background) was also 
collected and subsequently subtracted from the fluo-
rescence of the LW-1 peak. HPLC eluates were recon-
stituted to 2  ml with HPLC solvent and fluorescence 
was determined with a JASCO 821-FP detector. Percent 
fluorescence recovery for LW-1 was calculated as [(peak 
LW1–peak enzyme blank)/(injected collagen digest – 
enzyme blank)]*100.
Quantitative analysis of AGEs by liquid 
chromatography‑tandem mass spectrometry (LC‑MS/MS)
Fructosyl-lysine, glucosepane, CML, CEL, G-H1, 
MG-H1 were assayed by liquid chromatography—tan-
dem mass spectrometry (LC-MS/MS) using isotope 
dilution technique as recently published by us [20]. In 
short, each digest was filtered (as described above) fol-
lowed by injecting  ~40  µl onto a Waters 2695 Alliance 
HPLC system using two Hypercarb columns (Ther-
moFisher) connected in series. Separations were made 
using chromatographic methods described by Thornal-
ley et  al. [25]. The eluate was directed to a Micromass 
Quattro Ultima mass spectrometer (Waters) which 
monitors for both the molecular and product ion frag-
ments of each AGE assayed [23]. For this work, the 
values were obtained from our recent paper [20]. Pento-
sidine and collagen solubility values were taken from the 
1999 study [19].
Quality controls (QCs)
Since a large number of digests were injected onto the 
HPLC over the course of 6 weeks, assays were monitored 
for quality assurance by a Levey-Jennings plot (Addi-
tional file 2). For LW-1, the low and high quality controls 
(i.e., LQC and HQC) consisted of injecting standardized 
digests prepared from skin samples obtained at autopsy 
from a 22 and 38 year-old patient, respectively. Aliquots 
of LQC and HQC digests ~64 µg collagen in 10 µl were 
injected onto the HPLC approximately every 2–4  days 
while LW-1 used as a quality control (QC) standard was 
injected every day (~3 pmol in 5 µl).
Measurement of skin intrinsic fluorescence (SIF)
SIF was determined noninvasively on the left volar fore-
arm skin of patients at EDIC years 16–17 using the 
SCOUT DS instrument (Miraculins, Inc., Winnipeg, 
Manitoba, Canada) according to procedures detailed else-
where [18, 26]. For these analyses, the excitation (ex) was 
centered at 375  nm using a light-emitting diode (LED) 
followed by measuring fluorescence detected over the 
broadband emission (em) range of 435–655  nm. Meas-
urement of skin reflectance (R) was used to compensate 
for absorbance due to melanin and hemoglobin as well as 
subject-specific light scattering; i.e., individual differences 
due to the presence of wrinkles and hair follicles as well as 
dermal collagen concentration and organization [10]. An 
intrinsic fluorescence correction formula was used as fol-
lows: fex.em = Fex.em/(Rkexex Rkemem ) where the measured fluo-
rescence, Fex.em, is divided by reflectance values measured 
over both the excitation (Rex) and emission (Rem) regions. 
The reflectance values are adjusted by the dimensionless 
exponents, kex and kem, set to 0.6 and 0.2, respectively. The 
resulting intrinsic fluorescence fex.em was integrated over 
the 435–655 nm spectral region and multiplied by 1000 to 
represent SIF, reported in arbitrary units. The values used 
for kex and kem were previously determined in the Pitts-
burgh Epidemiology of Diabetes Complications (EDC) 
study to be relevant for the 375 nm excitation which had 
the strongest association with diabetes-related complica-
tions in the Pittsburgh EDC cohort [27]. In the present 
study, the first SIF measurement per subject was used for 
all plots and analyses [18, 26].
The specificity of the SCOUT for fasting plasma glu-
cose (FPG) was previously reported to be 77 % [10]. Like-
wise, the sensitivity of this instrument for FPG, HbA1C, 
and SIF (as contributable to dermal AGEs) was previ-
ously determined to be 58, 64 and 75 %, respectively [10].
The general technical requirements for the suitable non-
invasive estimation of the diabetic levels using a skin fluo-
rescence spectrometer have previously been published 
[10, 28, 29]. For noninvasive diabetes screening using 
the SCOUT, statistical analysis involving both principal 
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component and linear discriminant analyses were applied 
to SIF spectra to differentiate whether an individual 
belonged to the diabetic vs. nondiabetic group [10].
Cardiovascular disease (CVD) outcomes
Coronary artery calcification (CAC) was determined by 
computed tomography (CT) at EDIC years 7–9 by meth-
ods previously described [17]. Intima-media thickness 
(IMT) of the common carotid artery was measured by 
ultrasonography and image analysis at EDIC years 6 and 
12 according to procedures detailed elsewhere [30]. Left 
ventricular mass (LVM), volumes, and functional param-
eters were determined from short axis cine images cov-
ering the heart from base to apex throughout the cardiac 
cycle using cardiac magnetic resonance imaging (cMRI) at 
EDIC years 14–16 by methods previously described [31].
Statistics
The precision of the LW-1 assay was determined by intra-
day and inter-day coefficients of variability (% CV). The 
coefficient of variability (CV) was calculated as follows: 
% CV = (mean level/SD)*100 where SD: standard devia-
tion. Intra-day % CV was determined by repeated injec-
tions of the LW-1 standard on the same day over the 
6  week course of the assay. Inter-day % CV was deter-
mined by repeated injections of the LQC, HQC and the 
LW-1 QCs made on different days over the assay period 
for time points shown on the Levey-Jennings plot (Addi-
tional file  2). Linear regression analyses including com-
putation of the regression line and its 95  % confidence 
intervals (CI) of prediction were done using SigmaPlot 
11.0 software (Systat Software, Inc., San Jose, CA). The 
comparisons among LW-1, CLF and SIF were made by 
partial correlation analyses using SPSS v.11.5 software 
(IBM SPSS, Chicago, IL). All other statistical methods 
have been detailed elsewhere [19, 20] including Spear-
man correlation, linear regression models, multivariate 
logistic regression models, entropy R2, odds ratio and 
adjustment of multiple tests.
Results
Chromatographic analysis of LW‑1
Using the stated gradient method, LW-1 eluted 
at ≈86 min in the chromatograms (Additional file 1). A 
Levey-Jennings plot was constructed to monitor instru-
ment performance over time indicated no drift requiring 
an adjustment of the data (Additional file  2). Thus, the 
data were used “as is”. This analysis revealed an intra-day 
CV of <4 % for the LW1 QC standard and an inter-day 
CV of <4, 8 and 10 % for the high (HQC), low (LQC) and 
LW-1 QC standard, respectively. Of note is that LW-1 is 
the single major fluorescent peak in samples from both 
DCCT and control donors (Additional file 1).
LW‑1 correlation with age, diabetes duration and glycemic 
control
LW-1 significantly (P  <  0.0001) increased with age in 
the control individuals without diabetes as well as in the 
DCCT patients treated conventionally and intensively 
for glycemic control (Additional file  3). For this latter 
group, LW-1 responded well to intensive therapy in the 
primary prevention cohort (no retinopathy at baseline) 
but less well in the secondary intervention cohort (mild 
retinopathy at baseline) (Fig. 1b, c; Fig. 2). In the primary 
cohort, levels were significantly (P < 0.0001) lowered by 
intensive vs. conventional therapy with many of these 
data points within the 95 % CI determined for the con-
trols (Fig.  1b). In comparison, in the secondary cohort, 
intensive therapy lowered LW-1 in some patients, but 
less in others relative to conventional therapy, and many 
of the intensive group data points remained outside the 
95 % CI determined for the controls (Fig. 1c). Overall, the 
effect of intensive therapy was still significant (P = 0.037) 
in this cohort.
Spearman correlation analysis across DCCT treat-
ments showed that levels were significantly (P < 0.0001) 
elevated by both age and diabetes duration (data not 
shown). After adjustment for these two factors, analy-
sis reconfirmed that LW-1 levels were significantly 
(P = 0.0001) attenuated by intensive vs. conventional gly-
cemic treatment (Fig. 2). However, mean levels remained 
significantly (P  <  0.0001) elevated in patients undergo-
ing intensive therapy vs. the controls without diabetes 
(Fig. 2).
Correlation with AGEs
Regression analysis was used to explore the relation-
ship between LW-1 and other collagen markers meas-
ured by our laboratory in the DCCT. AGE markers 
including percent insolubility, CLF, fructosyl-lysine, 
glucosepane, pentosidine, CML, MG-H1 and CEL all 
correlated (r  =  0.15–0.70) significantly (P  <  0.02) with 
LW-1 (Additional file  4). Furthermore, except for CEL, 
the statistical significance for all these relationships 
persisted after LW-1 was adjusted for age and diabe-
tes duration in DCCT participants (Additional file  5). 
Interestingly, LW-1 most strongly correlated with glu-
cosepane: r = 0.6–0.7, P < 0.0001 (Additional file 4, Addi-
tional file  5) suggesting that glucose may be part of the 
LW-1 structure (see "Discussion" section).
Correlation of LW‑1 with Collagen‑Linked Fluorescence 
(CLF) and noninvasive Skin Intrinsic Fluorescence (SIF)
LW-1 accounted for up to ~30 % of CLF levels measured 
in chromatograms at ex/em 348/463 nm; i.e., the fluores-
cence maxima of LW-1 (Fig. 1a). As similar to the anal-
ysis in the above, LW-1 increased in DCCT patients vs. 
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the controls (P = 0.003) and decreased with intensive vs. 
conventional therapy (P = 0.005, Fig. 1a). The association 
with noninvasive SIF measured by SCOUT DS was posi-
tive and strongly significant even though SIF was deter-
mined 16–17 years after the skin biopsy used to measure 
LW-1 (Fig.  3). SIF significantly correlated with LW-1 
both before (P =  0.001, Fig.  3) and after age correction 
(P = 0.046, data not shown). In contrast, SIF significantly 
correlated with CLF before age correction (P  =  0.004, 
Fig. 3), but not after (P = 0.16, data not shown). In fur-
ther analysis, LW-1 significantly correlated with CLF 
(P < 0.0001), but not SIF (P = 0.084), after further correc-
tion for diabetes duration (Additional file 5). Thus, LW-1 
and CLF were more closely associated in this study due to 
measurements made within the same buttock skin biopsy 
(1993). In turn, unsurprisingly, these two measures were 
considerably less associated with SIF which was noninva-
sively measured on volar forearm skin many years later 
(2009–2010).
Correlation with indices of cumulative glycemia (HbA1c)
LW-1 was strongly associated with recent measures 
of glycemia such as at the time of biopsy (R2  =  10.1, 
P  <  0.0001) or the year preceding the biopsy (R2 =  9.6, 
P  <  0.0001) and significantly correlated with mean 
HbA1c  ~7–10  years prior to the biopsy (R2  =  9.9, 
P  <  0.0001). As expected, it correlated less with glyce-
mia at initial screening (R2  =  2.7, P  <  0.015). Subse-
quently, ≈10 % of variation in LW-1 levels was explained 
by HbA1c (Additional file 6).
Correlation with past and future progression 
of microvascular complications
LW-1 was evaluated with respect to patient complica-
tions which progressed over the DCCT, but limited to 
patients with no respective complication at DCCT base-
line with exclusions (see Fig. 4). Complications included 
retinopathy, nephropathy and neuropathy (Fig.  4) with 
clinical outcomes defined according to DCCT crite-
ria [19, 20, 32] as either sustained 3-step progression in 
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Fig. 1 Unadjusted LW-1 vs. age in skin collagen digests of DCCT patients. For all graphs, regression lines and 95 % CI prediction for nondiabetic 
controls are shown. a Unadjusted LW-1 expressed as a percentage of total fluorescence at ex/em 348/463 nm in skin collagen digests vs. age. 
Percent LW-1 was determined by manually collecting the LW-1 peak by HPLC and comparing its fluorescence yield with that of the digest itself at 
wavelengths same as described in the “Methods” section. b and c Unadjusted LW-1 levels vs. age at DCCT closeout in the primary and secondary 
cohorts. Regression lines: a y = 3.4 + 0.172x, r = 0.48, P = 0.002, n = 39. b and c y = 1.8 + 6.6x, r = 0.64, P < 0.0001, n = 42. Treatment (cohort) 
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Fig. 2 The effect of intensive vs. conventional glycemic therapy on 
LW-1 levels after adjustment for age and diabetes duration in the pri-
mary and secondary DCCT cohorts at DCCT closeout. LW-1 responds 
significantly to lowering of glycemia after adjusting for age and 
duration of diabetes (nondiabetic controls: age-adjusted). Each bar 
represents the mean ± SD. Means with a different letter superscript 
are significantly different (P ≤ 0.0001)
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retinopathy, sustained ≥3 microaneurysms (retinopathy), 
albumin excretion rates  >40  mg/24  h (nephropathy), or 
motor nerve abnormalities (neuropathy). In these evalu-
ations, univariate regression analyses were used to model 
type of complication vs. LW-1 levels after adjustment for 
age and diabetes duration averaged across all treatments 
and cohorts (Fig. 4). The results showed that mean levels 
of LW-1 were elevated in patients for all complications 
listed in Fig. 4 with significant associations with microa-
neurysms (P = 0.0004) and AER (P = 0.0038). Similarly, 
at EDIC years 13–16, age and duration-adjusted LW-1 
levels were significantly (P  =  0.023) associated with 
3-step progression of retinopathy (Table  1). Following 
adjustment for HbA1c up to the time of biopsy; i.e., mean 
HbA1c during the DCCT, AER was the only complication 
that remained significant (P = 0.036, Table 1).
Correlation of LW‑1 with subclinical macrovascular 
complication progression compared with CLF 
and noninvasive SIF
Spearman correlation analysis (univariate) was used to 
compare all three currently known fluorescent mark-
ers for their associations with subclinical cardiovascu-
lar disease progression. The results show that LW-1 was 
borderline nonsignificantly (P  =  0.055) associated with 
CAC; i.e., continuous CAC score and CAC score  >0 
(Fig. 5). However, these associations were much stronger 
for CLF (P < 0.0001) and SIF (P = 0.0002) whereby CLF 
was the only parameter that was significantly associated 
with the severity of CAC score; i.e., CAC = 0 vs. CAC > 0 
(P = 0.0004) or CAC < 100 vs. CAC > 100 (P = 0.003). 
Both LW-1 and CLF were weakly (P  <  0.05) associated 
with IMT change at EDIC year 6 and 12, respectively. 
In comparison, SIF was significantly (P  <  0.01) associ-
ated with IMT progression at both 6 and 12 years (data 
not shown). Finally, left ventricular mass (LVM) was 
selectively associated with LW-1 (P  =  0.011) and CLF 
(P  =  0.0075) while SIF was associated (P  <  0.01) with 
ejection fraction (data not shown).
Multivariate regression analyses were performed 
to investigate the effects of adjustment for age, diabe-
tes duration and especially HbA1c during the DCCT 
and EDIC phase of the study. In short, these analy-
ses showed that CAC was significantly associated with 
CLF (P  ≤  0.021) and SIF (P  ≤  0.046); IMT with LW-1 
(P  ≤  0.02) and SIF (P  <  0.01); and LVM with LW-1 
(P  ≤  0.008) and CLF (P  ≤  0.035). Subsequently, linear 
plots were made of these significant associations which 
are shown in Figs. 6 and 7 for IMT and LVM, respectively.
Discussion
Issues using autofluorescence/LWF as a marker 
for accumulation of AGEs
LWF has traditionally been used as a marker and meas-
ure for AGE modifications in skin studies both in vivo 
[12, 33] and in vitro; e.g., reconstructed skin model 
for aging of human skin [34]. A number of issues have 
arisen in the assessment of AGEs by LWF which need to 
be considered in the interpretation of the results. First, 
as previously mentioned, LWF is structurally poorly 
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Symbols used: see Fig. 1
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defined in that other molecules besides AGEs may fluo-
resce and contribute to measured levels. Undoubtedly, 
however, as presented in another paper by us involving 
the same DCCT/EDIC patients [35], many important 
AGEs are not fluorescent and significantly increase with 
the progression of diabetes and CVD. Secondly, LWF 
is significantly and highly influenced by chronological 
age. For example, in a study of obesity in healthy indi-
viduals, LWF measured by the AGE Reader as SAF sig-
nificantly increased in the skin of obese compared with 
non-obese subjects; i.e., attributable to accelerated AGE 
formation, but the statistical difference between the two 
cohorts was abolished after the correction for age and 
smoking [12]. Likewise, in another study, both CLF and 
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(P > 0.05). Analysis was limited to those with no respective complication at DCCT baseline (excluding 10 subjects with AER > 40, 19 with confirmed 
clinical neuropathy, and the secondary cohort for sustained ≥3 MA). Indices of retinopathy, microaneurysms, nephropathy and neuropathy were 
quantified as previously described [19]. ‡ P value is from a Likelihood Ratio test (LRT) between the respective reduced model and the full model
Table 1 Logistic regression models of microvascular complications vs. age- and duration-adjusted LW-1 levels with and 
without adjustment for DCCT mean HbA1c up to the biopsy across treatment groups
Abbreviations used: see Fig. 4. Analysis limited to those with no respective complication at DCCT baseline excluding 10 subjects with AER >40 mg/24 h and the 
secondary cohort for sustained ≥3 MA
a Unadjusted models are from univariate logistic regression with LW-1 or DCCT mean HbA1c up to the biopsy time as the risk factor
b Adjusted models are from logistic regressions with both LW-1 and the DCCT mean HbA1c up to the biopsy time as risk factors
c Odds ratio is calculated based on one SD increase in LW-1; i.e., 170
d Entropy R2 is calculated as the ratio of Chi square from a likelihood ratio test and −2*log transformation of the likelihood from the null model with intercept only
e P value is from the Likelihood Ratio Test (LRT) between the respective reduced vs. full model
Outcome Total 
N
Event 
N
LW‑1a LW‑1 Adjusted for HbA1c b DCCT Mean 
HbA1ca
DCCT Mean HbA1c 
Adjusted for LW‑1b
Odds ratioc Entropy 
R2d
P valuee Odds ratioc Entropy 
R2d
P valuee Entropy 
R2d
P valuee Entropy 
R2d
P valuee
DCCT complications (at DCCT closeout)
 Retinopathy/ 
microaneurysms 
(sustained ≥3 
MA ever in DCCT) 
(primary cohort)
123 31 1.97 (1.40, 3.27) 9.0 0.0004 1.66 (1.00, 2.33) 2.3 0.077 (NS) 14.9 <0.0001 8.1 0.0008
 Nephropathy (AER 
closest to biopsy  
> 40 mg/24 h)
206 15 1.97 (1.19, 3.27) 7.8 0.0038 1.66 (1.00, 2.76) 4.1 0.0357 8.3 0.0028 4.6 0.0259
EDIC complications (EDIC years 13–16)
 Retinopathy/ 
progression (3 or 
more step  
progression)
213 91 1.37 (1.04, 1.81) 1.8 0.023 1.09 (0.80, 1.48) 0.1 0.58 (NS) 10.5 <0.0001 8.8 <0.0001
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SAF were significantly and positively correlated with 
pulse wave velocity (PWV) in association with vascular 
stiffness and function in patients with coronary heart 
disease [33]. However, no adjustment was made for the 
covariance of age among these variables, thus making 
the interpretation of the relationship between LWF and 
PWV obscured. Thirdly, the relationship between LWF 
and glycemia has not always been definitive, but defi-
nitely more correlative for hyperglycemic vs. normogly-
cemic conditions. For example, in the obesity study just 
mentioned by den Engelsen [12], there was no associa-
tion between SAF and fasting blood glucose even though 
the obese individuals had significantly (P < 0.001) higher 
blood glucose levels vs. the non-obese (mean 90  ±  18 
vs. 86 ±  11  mg/dl, respectively). Similarly, in the coro-
nary heart disease study by Hofmann et  al. [33], there 
was no association between CLF and blood glucose 
(114 ± 36 mg/dl) or HbA1c (6.3 ± 0.7 %). However, this 
study consisted of a small number of patients (n =  52) 
with and without type 2 diabetes (n  =  19). In a large 
clinical trial involving n  =  1185 DCCT/EDIC patients 
with type 1 diabetes, SIF positively and significantly cor-
related (r = 0.26, P < 0.0001) with 25 year mean HbA1c 
(overall mean 8.0 ±  1  %, range ≈5–12  %) whereby the 
correlation got even stronger (r  =  0.46) after SIF was 
adjusted for a host of factors including age, smoking, 
skin tone, glomerular filtration rate and clinic latitude 
[18].
Fig. 5 Spearman correlations for markers of skin fluorescence vs. coronary artery calcification (CAC). Markers were adjusted for age and diabetes 
duration. CAC was determined at EDIC years 7–9 by computed tomography as scores in Agatson units
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The relationship of LW‑1 with age and glycemic therapy 
in the treatment of type 1 diabetes
The above results show that LW-1 levels increased 
with age in insoluble skin collagen from both DCCT 
and control individuals and its formation was further 
catalyzed by type 1 diabetes. LW-1 levels measured 
in this tissue near DCCT closeout were significantly 
reduced after glucose levels were lowered by intensive 
therapy over the 9 year period of the DCCT. This effect 
was most pronounced in the primary prevention cohort 
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and less so in the secondary intervention cohort. Not 
surprisingly, similar results were previously observed 
for other markers measured by our laboratory [19, 20, 
35] since the secondary cohort had longer duration of 
diabetes and the presence of complications at baseline 
vs. the primary cohort with shorter duration of diabe-
tes and no complications at baseline. In other words, 
LW-1 formation is more easily prevented, or even 
reversed the younger the age and the less advanced the 
disease are.
The relationship of LW‑1 with glycemia and diabetic 
complications
Our previous studies on the relationship between skin 
collagen markers and glycemia revealed associations with 
past cumulative glycemia that varied in strength depend-
ing upon the analyte. For example, glucosepane was 
strongly associated with mean glycemia at all time points 
during the DCCT from baseline on [20]. Here we found 
that LW-1 correlates with both recent and long-term gly-
cemia, explaining up ≈10  % of the variability in HbA1c 
levels. This suggests that LW-1 may be potentially valu-
able for the assessment of diabetic complications related 
to hyperglycemia.
In comparison, in the analysis of LW-1 association 
with microvascular complications, levels adjusted for 
age and duration increased in all diabetic complica-
tion outcomes studied, although statistical signifi-
cance was reached only for microaneurysms and AER. 
At follow-up in EDIC, adjusted levels were signifi-
cantly associated with 3-step progression of retinopa-
thy 13–16  years following DCCT closeout. However, 
in all these analyses, except for AER (P =  0.036), the 
associations were weakened by further adjustment 
for HbA1c perhaps suggesting that LW-1 has a more 
important role as a marker rather than a culprit of 
microvascular disease. These results also suggests that 
the predictive effect of LW-1 on microvascular com-
plications is to some extent mediated by glycemia and 
that LW-1 may be more proximal to the causal mecha-
nism by which HbA1c affects outcomes. In this regard, 
our recent study showed that several AGEs were much 
more strongly associated with microvascular disease 
progression in spite of adjustment for mean glycemia 
than LW-1 [32]. The order for retinopathy was (strong-
est to weaker) glucosepane  >  fructose-lysine (furo-
sine)  >  other AGEs; for nephropathy, fructose-lysine 
(furosine)  >  other AGEs; and for neuropathy, methyl-
glyoxal hydroimidazolone (MG-H1)  >  fructose-lysine 
(furosine) > other AGEs.
Concerning the macrovascular complications, LW-1 
was found most significantly related to carotid IMT and 
cardiac LVM as outcome markers for atherosclerosis and 
cardiac hypertrophy/dysfunction, respectively. Impor-
tantly, unlike the microvascular outcomes evaluated 
above, statistical significance for IMT and LVM remained 
significant even after adjustment for HbA1c levels (Figs. 6, 
7). These observations may be related to our previous 
finding that LW-1 levels are highly elevated in patients 
with renal failure, especially those with end-stage renal 
disease undergoing dialysis [15]. The latter is well known 
to greatly accelerate CVD outcomes including athero-
sclerosis [36] and heart hypertrophy [37]. Conversely, 
none of the DCCT/EDIC participants in this study were 
in renal failure and accordingly LW-1 was not associated 
with CAC outcome as a marker for atherosclerosis.
The relationship of SAF/SIF measured by skin readers 
with diabetic complications
Numerous studies with the skin readers have shown 
that autofluorescence correlated strongly with the 
development of nephropathy [38] and neuropathy [39] 
including its association with the development of dia-
betic foot ulcers [40]. Conversely, its association with 
retinopathy was not nearly as strong. Its statistical sig-
nificance was highly dependent upon whether levels 
were corrected for confounding risk factors of diabetic 
complications; namely, age, duration of diabetes and 
HbA1c. Subsequently, the relationship between SAF 
with the development of retinopathy was found signifi-
cant after adjustment for age [41], but not after adjust-
ment for duration [41] and/or HbA1c [9]. Furthermore, 
in a prospective study with a follow-up period of over 
3  years  involving 967 patients with type 2 diabetes, no 
significant relationship between SAF and retinopathy was 
found [42].
The relationship of CLF with glycemia and diabetic 
complications
Previously, we showed that skin CLF at ex/em 
370/440 nm accounted for up to ≈7 % of the variation in 
HbA1c levels at DCCT closeout [19] vs. 10 % for LW-1 
in the present study. After adjustment for age and dura-
tion, CLF was significantly associated with nephropathy 
and neuropathy, but not retinopathy [19]. Prospectively, 
age- and duration-adjusted CLF determined at DCCT 
closeout significantly increased in relationship with the 
progression of nephropathy (P = 0.0033) and retinopa-
thy (P = 0.0008) at EDIC years 9–10, but the statistical 
significance was nullified by the further adjustment of 
levels for HbA1c [43]. Thus, CLF is not a robust marker 
for microvascular disease compared with fructose-
lysine (furosine), glucosepane and MG-H1 as discussed 
above.
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The significance of LW‑1 as a marker for diabetic 
complications in comparison with other fluorescent 
and non‑fluorescent markers
The significance of LW-1 as a marker, or possible culprit 
of complications, depends on two conditions; i.e., its bio-
chemical origin and its ability to possibly predict com-
plication progression better than other fluorescent and 
non-fluorescent AGEs. Concerning the first condition, its 
biochemical origin is still under investigation. The second 
issue is in part the topic of this study and is closely related 
to commercially-introduced diagnostic devices that 
measure autofluorescence of human forearm skin using 
broadband fluorescence technology. Together, these pre-
vious studies revealed that autofluorescence measured by 
the skin readers was strongly associated with age, renal 
failure and diabetes [44, 45]. For diabetes, autofluores-
cence levels were associated with both micro- and mac-
rovascular complications, cardiovascular mortality, and 
all-cause mortality [46] [reviewed by Bos et al. [47] ]. In 
type 1 diabetes, these levels were directly correlated with 
coronary artery disease [38] and CAC [27], and inversely 
correlated with elasticity of both small and large arteries 
[11]. Additionally, these levels also increased in subjects 
with artery stenosis and peripheral artery disease [48].
Questions persist as to whether LW-1 is better than 
other markers in terms of its significance and detect-
ability in  vivo; i.e., its ability to be technically separated 
from other AGE fluorescence. This first question has 
been addressed in the correlative statistical analyses of 
subclinical endpoints with fluorescent markers. Using 
Spearman correlations and the recently published data 
on non-fluorescent AGEs [35], the order of significance 
for IMT was LW-1 > pepsin soluble collagen > fructose-
lysine  >  glucosepane  >  CLF (all P  <  0.05). Except for 
fructose-lysine (furosine), none of the traditional AGEs 
predicted CAC while LW-1 was only borderline associ-
ated with it (P = 0.055). LW-1 was the strongest predictor 
of left ventricular mass together with CML (P = 0.01) fol-
lowed by pepsin soluble collagen and MG-H1 (P < 0.05).
In regard to the second question, deconvolution anal-
ysis of total fluorescence at ex/em 370/440  nm is cer-
tainly feasible and might be helpful for documenting 
the complexity of the compounds contributing to total 
fluorescence. However, limited structural information is 
expected from such analysis which is a major reason why 
we have not so far attempted to deconvolute CLF into its 
subcomponents.
The strong correlation of LW‑1 with glucosepane 
towards the putative structure of LW‑1
LW-1 significantly correlated with other markers meas-
ured by our laboratory both before and after adjustment 
for age and diabetes duration. The strongest association 
was with glucosepane suggesting glucose may be part 
of the LW-1 structure. Yet, the biochemical relation-
ship between LW-1 and glycation is still unclear. LW-1 
is a highly fluorescent lysine-derived amino acid with a 
molecular weight of 623 Da, a UV maximum at 348 nm 
and fluorescent maxima at (ex/em) 348/463  nm due to 
an aromatic ring [15]. This agrees with our HSQC (het-
eronuclear single quantum coherence) 2D-NMR data 
which shows signals indicative of a 6-carbon sugar [15]. 
Finally, LW-1 is a major collagen modification with levels 
approaching those of glucosepane, the single major AGE 
and collagen crosslink in diabetic tissues. At this point 
however, a complete structure is not available yet and 
further work is needed to fully resolve its structure.
Summary of the relationship between LW‑1, CLF and SIF
The interrelationship between the three types of fluo-
rescence referenced in this study can be summarized as 
follows: The specific LW-1 fluorophore contributes up to 
30 % and perhaps more of total skin CLF measured at ex/
em 348/363 nm. On the other hand, both CLF and LW-1 
correlate strongly with autofluorescence (AF) (r  =  0.2) 
[49]. However, CLF presumably also comprises other yet 
unidentified types of fluorophores that may not neces-
sarily be associated with diabetic complications. Indeed, 
while AF/SIF are associated with severity of compli-
cations, two recent genome-wide association studies 
(GWAS) mention loci [50, 51] or coffee consumption [52] 
as being associated with skin fluorescence and type 1 dia-
betes, but not diabetic complications [50, 51].
Conclusion
A major conclusion from the above studies is that LW-1 
is an important long-term risk factor for the develop-
ment of IMT and LVM associated with macrovascular 
disease. This risk factor remained significant after further 
adjustment for HbA1c. Vice versa, HbA1c was not signifi-
cantly associated with either IMT or LVM. Interestingly, 
while glucose-derived AGEs such as fructose-lysine/furo-
sine and glucosepane are very strongly associated with 
microvascular disease [20, 32], these same markers are 
superseded by the fluorescent species in their association 
with progression of subclinical macrovascular disease. 
All three fluorescence markers reported here show some 
degree of correlation among each other, yet progress in 
structure elucidation of LW-1 and a precise understand-
ing of the molecular basis of skin autofluorescence will be 
needed to understand their role in the elusive mechanis-
tic link between hyperglycemia and the acceleration of 
macrovascular disease in diabetes.
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Additional files
Additional file 1. HPLC-fluorescence chromatograms of LW-1 eluting 
from a 15 cm X 2.1 mm, 3 μm Discovery HS C18 column. For the standard, 
LW-1 ~ 6 pmoles was injected in a 10 μl volume. For DCCT samples, 
including the nondiabetic, digests of insoluble collagen prepared from 
skin biopsies were injected onto the HPLC in 14 μl volumes, each contain-
ing ~ 61 to 69 μg collagen. The low and high quality controls (LQC and 
HQC) consists of collagen digests prepared from autopsied skin samples 
from a 22 and 38 year-old patient, respectively (see Methods). The former 
died from meningitis while the latter died from ESRD secondary to type 
1 diabetes. Totals of 64 μg collagen in 10 μl were injected onto the HPLC 
column. Peaks eluting > 100 minutes represent column washing and 
equilibration (see "Methods" section).
Additional file 2. Levey-Jennings plot for LW-1 assay in the DCCT study. 
The plot consists of injection number on the x-axis (i.e., from 1 to 357 in 
consecutive order over the six week course of the HPLC assay) vs. inte-
grated peak areas on the y-axis (relative fluorescence at ex/em 348/463 
nm) for all samples injected (n = 216 DCCT + n = 42 nondiabetic controls 
+ n = 13 repeats), LQC (n = 13), HQC (n = 14), LW-1 QC standard (n = 49) 
and enzyme blanks (n = 10).
Additional file 3. LW-1 levels increase with age in insoluble skin collagen 
of DCCT participants at DCCT closeout (x: age, y: LW-1). Controls: subjects 
without diabetes, regression line and 95 % CI prediction, y = 0.05 + 
7x, r = 0.64, P < 0.0001, n = 42. Conventional: regression line (dash line) 
y = 21 + 13x, r = 0.43, P < 0.0001, n = 94. Intensive: regression line (dash 
line) y = 11x - 22, r = 0.42, P < 0.0001, n = 122. The regression line and 
95 % CI for the controls have been reproduced in the latter two graphs for 
comparison. Symbols used: treatment (cohort): squares, controls; circles, 
conventional (primary); triangle, conventional (secondary); filled circle, 
intensive (primary); filled triangle, intensive (secondary) 
Additional file 4. Plots of unadjusted LW-1 levels vs. AGEs measured 
in insoluble skin collagen in the combined dataset: i.e., DCCT (n = 216) 
plus nondiabetic controls (n = 42). Levels of all measured parameters 
except collagen insolubility (%) and CLF (arbitrary fluorescence units/mg 
collagen) are stated in picomoles per mg collagen. For each graph, the 
linear regression line and 95 % CI prediction determined for the combined 
dataset are shown along with its correlation coefficient and statistical 
significance (P value). Symbols used: see Additonal file 3.
Additional file 5. Partial correlation analysis of LW-1 with other skin col-
lagen markers controlling for age and duration of diabetes.
Additional file 6. LW-1 correlates better with recent rather than long-
term cumulative glycemia. Univariate regression models of age- and 
duration-adjusted LW-1 (biopsy) vs. HbA1c at different sampling times in 
the DCCT.
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